Loading...
OTCM
ATXI
Market cap2mUSD
Dec 05, Last price  
0.77USD
1D
-3.88%
1Q
4.63%
IPO
-99.99%
Name

Avenue Therapeutics Inc

Chart & Performance

D1W1MN
OTCM:ATXI chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
65.34%
Rev. gr., 5y
%
Revenues
0k
Net income
-12m
L+12.29%
-5,226,000-3,177,000-12,258,000-21,280,000-25,551,000-5,089,000-3,724,0002,048,000-10,377,000-11,652,000
CFO
-9m
L-4.50%
-895,000-1,632,000-6,802,000-18,216,000-26,259,000-4,613,000-3,750,000-7,596,000-9,451,000-9,026,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
URL
https://avenuetx.com/
IPO date
Jun 27, 2017
Employees
2
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT